AZD3470

Small molecule

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1/2 (2)
Other / comorbidity
NCT06137144 · AstraZeneca
2024-01-23 – 2029-05-03 · Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL), PTCL-NOS, ALCL, AITL
What this study did
NCT06130553 · AstraZeneca
2024-01-18 – 2028-12-04 · Advanced Solid Tumors That Are MTAP Deficient
What this study did

Competitive landscape

6 other tracked programmes target this mechanism, none of them ahead of this one.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
AZD3470: this drugPhase 1/2Small moleculePRMT5not yet gradedNo reviewed efficacy summary
BAY 3713372
Phase 1/2(overall)
Small moleculePRMT5not yet gradedNo reviewed efficacy summary
TNG456
Phase 1/2(overall)
Small moleculePRMT5not yet gradedNo reviewed efficacy summary
Vopimetostat
Phase 1/2(overall)
Small moleculePRMT5not yet gradedNo reviewed efficacy summary
HSK41959
Phase 1(overall)
Small moleculePRMT5not yet gradedNo reviewed efficacy summary
IDE892
Phase 1(overall)
Small moleculePRMT5not yet gradedNo reviewed efficacy summary
Ralometostat
Discontinued
Small moleculePRMT5not yet gradedNo reviewed efficacy summary

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow AZD3470 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
December 2028 (1)
Phase 1/2Advanced Solid Tumors That Are MTAP DeficientRecruiting
Est. primary completion 2028-12-04 · NCT06130553 · CT.gov ↗
What to watch
2029 (1)
May 2029 (1)
Phase 1/2Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL), PTCL-NOS, ALCL, AITLRecruiting
Est. primary completion 2029-05-03 · NCT06137144 · CT.gov ↗
What to watch

See the full readout calendar ↗